Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart

Xenobiotica

Volumn 42, Issue 12, 2012, Pages 1235-1247

  Anwar Mohamed, Anwar ^a   El Sherbeni, Ahmed A ^a   Kim, Seok H ^a   Althurwi, Hassan N ^a   Zordoky, Beshay N M ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Arachidonic acid metabolism; Arsenic; Cardiac hypertrophy; Cytochrome P450s; Dihydroxyeicosatrienoic acids; Epoxyeicosatrienoic acids; Epoxygenases; Hydroxylases; Soluble epoxide hydrolase

Indexed keywords

11,12 DIHYDROXYEICOSATRIENOIC ACID; 11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 DIHYDROXYEICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 8,9 DIHYDROXYEICOSATRIENOIC ACID; ARACHIDONIC ACID; ARSENIC; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 4F; EPOXIDE HYDROLASE; ICOSANOID; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; C57BL 6 MOUSE; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ARACHIDONIC ACID; ARSENIC; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOMEGALY; CYCLOOXYGENASE 2; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING; SOLUBILITY; TOXICITY TESTS, ACUTE;

MUS;

EID: 84867663935     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.693971     Document Type: Article

References (51)

1. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y. (2007). Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 104:9018-9023.
2. Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, Zhu Y. (2009). Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 106:564-569.
3. Anwar-Mohamed A, El-Kadi AO. (2010). Arsenite down-regulates cytochrome P450 1A1 at the transcriptional and posttranslational levels in human HepG2 cells. Free Radic Biol Med 48:1399-1409.
4. Anwar-Mohamed A, Elbekai RH, El-Kadi AO. (2009). Regulation of CYP1A1 by heavy metals and consequences for drug metabolism. Expert Opin Drug Metab Toxicol 5:501-521.
5. Anwar-mohamed A, Zordoky BN, Aboutabl ME, El-Kadi AO. (2010). Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 61:410-418.
6. Barakat MM, El-Kadi AO, du Souich P. (2001). L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci 69:1559-1571.
7. Bhattacharyya KK, Brake PB, Eltom SE, Otto SA, Jefcoate CR. (1995). Identification of a rat adrenal cytochrome P450 active in polycyclic hydrocarbon metabolism as rat CYP1B1. Demonstration of a unique tissue-specific pattern of hormonal and aryl hydrocarbon receptor-linked regulation. J Biol Chem 270:11595-11602.
8. Bunderson M, Brooks DM, Walker DL, Rosenfeld ME, Coffin JD. & Beall HD. (2004). Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol 201: 32-39.
9. Chábová VC, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, Vanourková Z, Kolský A, Imig JD, Cervenka L. (2007). Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol 47:145-159.
10. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. (2004). Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32: 840-847.
11. Cui X, Kobayashi Y, Akashi M, Okayasu R. (2008). Metabolism and the paradoxical effects of arsenic: Carcinogenesis and anticancer. Curr Med Chem 15:2293-2304.
12. Das J, Ghosh J, Manna P, Sinha M, Sil PC. (2009). Taurine protects rat testes against NaAsO(2)-induced oxidative stress and apoptosis via mitochondrial dependent and independent pathways. Toxicol Lett 187:201-210.
13. Davey JC, Nomikos AP, Wungjiranirun M, Sherman JR, Ingram L, Batki C, Lariviere JP, Hamilton JW. (2008). Arsenic as an endocrine disruptor: Arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis. Environ Health Perspect 116:165-172.
14. Felix K, Manna SK, Wise K, Barr J, Ramesh GT. (2005). Low levels of arsenite activates nuclear factor-κB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol 19:67-77.
15. Ghosh J, Das J, Manna P, Sil PC. (2009). Taurine prevents arsenicinduced cardiac oxidative stress and apoptotic damage: Role of NF-κB, p38 and JNK MAPK pathway. Toxicol Appl Pharmacol 240:73-87.
16. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M, Hori M. (2002). Involvement of nuclear factor-κB and apoptosis signalregulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105:509-515.
17. Imig JD. (2004). 20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis? Am J Physiol Regul Integr Comp Physiol 287:R3-R5.
18. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
19. Kimes BW, Brandt BL. (1976). Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98:367-381.
20. Kroetz DL, Zeldin DC. (2002). Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 13:273-283.
21. Kumazaki M, Ando H, Sasaki A, Koshimizu TA, Ushijima K, Hosohata K, Oshima Y, Fujimura A. (2011). Protective effect of a-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats. J Pharmacol Sci 115:244-248.
22. Lin FH, Stohs SJ, Birnbaum LS, Clark G, Lucier GW, Goldstein JA. (1991). The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the hepatic estrogen and glucocorticoid receptors in congenic strains of Ah responsive and Ah nonresponsive C57BL/6J mice. Toxicol Appl Pharmacol 108:129-139.
23. Liu J, Liu Y, Powell DA, Waalkes MP, Klaassen CD. (2002). Multidrugresistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 170:55-62.
24. Liu L, Chen C, Gong W, Li Y, Edin ML, Zeldin DC, Wang DW. (2011). Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 339:451-463.
25. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. (2007). Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47:87-98.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
27. Lv X, Wan J, Yang J, Cheng H, Li Y, Ao Y, Peng R. (2008). Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 596:118-126.
28. Maier A, Dalton TP, Puga A. (2000). Disruption of dioxin-inducible phase I and phase II gene expression patterns by cadmium, chromium, and arsenic. Mol Carcinog 28:225-235.
29. Manimaran A, Sarkar SN, Sankar P. (2010). Influence of repeated preexposure to arsenic on acetaminophen-induced oxidative stress in liver of male rats. Food Chem Toxicol 48:605-610.
30. Mathews V, Desire S, George B, Lakshmi KM, Rao JG, Viswabandya A, Bajel A, Srivastava VM, Srivastava A, Chandy M. (2006). Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia 20:881-883.
31. Medina-Díaz IM, Estrada-Muñiz E, Reyes-Hernández OD, Ramírez P, Vega L, Elizondo G. (2009). Arsenite and its metabolites, MMA(III and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. Toxicol Appl Pharmacol 239:162-168.
32. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. (2008). Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 51:1379-1385.
33. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, Gross V, Hummel O, Maatz H, Patone G, Saar K, Vingron M, Weldon SM, Lindpaintner K, Hammock BD, Rohde K, Dietz R, Cook SA, Schunck WH, Luft FC, Hubner N. (2008). Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40:529-537.
34. Morisseau C, Hammock BD. (2007). Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protocol Toxico, 33, 1-18.
35. Patel HV, Kalia K. (2010). Sub-chronic arsenic exposure aggravates nephrotoxicity in experimental diabetic rats. Indian J Exp Biol 48:762-768.
36. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Kantarjian H, Estey E. (2006). Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res 30:362-363.
37. Piscaglia F, Knittel T, Kobold D, Barnikol-Watanabe S, Di Rocco P, Ramadori G. (1999). Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Biochem Pharmacol 58:157-165.
38. Rahman MM, Ng JC, Naidu R. (2009). Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environ Geochem Health 31 Suppl 1:189-200.
39. Ramanathan K, Shila S, Kumaran S, Panneerselvam C. (2003). Protective role of ascorbic acid and α-tocopherol on arsenicinduced microsomal dysfunctions. Hum Exp Toxicol 22: 129-136.
40. Roman RJ. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
41. Seubert JM, Webb CD, Bend Jr. (2002). Acute sodium arsenite treatment induces Cyp2a5 but not Cyp1a1 in the C57Bl/6 mouse in a tissue (kidney) selective manner. J Biochem Mol Toxicol 16:96-106.
42. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. (2007). Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82:50-59.
43. Umannová L, Zatloukalová J, Machala M, Krcmár P, Májková Z, Hennig B, Kozubík A, Vondrácek J. (2007). Tumor necrosis factor-α modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver "stem-like" cells. Toxicol Sci 99:79-89.
44. Wu JP, Chang LW, Yao HT, Chang H, Tsai HT, Tsai MH, Yeh TK, Lin P. (2009). Involvement of oxidative stress and activation of aryl hydrocarbon receptor in elevation of CYP1A1 expression and activity in lung cells and tissues by arsenic: An in vitro and in vivo study. Toxicol Sci 107:385-393.
45. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock BD, Chiamvimonvat N. (2006). Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103:18733-18738.
46. Yáñez L, Carrizales L, Zanatta MT, Mejía JJ, Batres L, Díaz-Barriga F. (1991). Arsenic-cadmium interaction in rats: toxic effects in the heart and tissue metal shifts. Toxicology 67:227-234.
47. Yousif MH, Benter IF, Roman RJ. (2009). Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton Autacoid Pharmacol 29:33-41.
48. Zhao X, Feng T, Chen H, Shan H, Zhang Y, Lu Y, Yang B. (2008). Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity. Basic Clin Pharmacol Toxicol 102:419-425.
49. Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD. (2006). PPAR-α activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol 290:H2187-H2195.
50. Zordoky BN, Aboutabl ME, El-Kadi AO. (2008). Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol- induced cardiac hypertrophy in rats. Drug Metab Dispos 36:2277-2286.
51. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. (2010). Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242:38-46.